细胞自噬在非小细胞肺癌中的研究进展

doi:10.20047/j.issn1673-7210.2023.27.07

摘要
图/表
参考文献(36)
相关文章 (15)

全文: PDF (488 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要肺癌是死亡率较高的恶性肿瘤，其中非小细胞肺癌（NSCLC）占肺癌的85%以上。NCSLC的治疗方法主要包括手术治疗、放疗、化疗、免疫治疗等。目前，放疗、化疗对肺癌的治疗效果尚不能让人满意，免疫治疗只对特定人群有效，且容易出现耐药现象，因此，亟须研发新的NSCLC治疗方法。自噬被报道可能是影响NSCLC发生及发展的重要因素之一。本文通过分析自噬在肿瘤中发挥的双刃剑作用，综述自噬在影响化疗、放疗、免疫治疗对NSCLC的疗效、敏感性及NSCLC耐药中起到的作用，为开发NSCLC新的治疗方案及发现新的生物标志物提供线索。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	刘梓键　　杨志雄

关键词 ：自噬, 非小细胞肺癌, 细胞程序性死亡, 化疗

Abstract：Lung cancer is a malignant tumor with a high mortality rate, with non-small cell lung cancer (NSCLC) accounting for over 85% of lung cancer. The treatments for NCSLC mainly include surgery, radiotherapy, chemotherapy,immunotherapy, and so on. At present, the therapeutic effects of radiotherapy and chemotherapy on lung cancer are not satisfactory. Immunotherapy is only effective for specific populations and is prone to drug resistance. Therefore, there is an urgent need to develop new NSCLC treatment methods. Autophagy has been reported to be one of the important factors affecting the occurrence and development of NSCLC. This article analyzes the double-edged sword role of autophagy in tumors, reviews the role of autophagy in influencing the efficacy, sensitivity and drug resistance of chemotherapy, radiotherapy, and immunotherapy for NSCLC, and provides clues for the development of new treatment strategies for NSCLC and the discovery of new biomarkers.

Key words： Autophagy Non-small cell lung cancer Programmed cell death Chemotherapy

基金资助:国家自然科学基金面上项目（81871883）。

通讯作者: 杨志雄（1963.8-），男，主任医师；研究方向：肺癌。

引用本文:

刘梓键　　杨志雄. 细胞自噬在非小细胞肺癌中的研究进展[J]. 中国医药导报, 2023, 20(27): 35-38.
LIU Zijian YANG Zhixiong. Research progress of cell autophagy in non-small cell lung cancer. 中国医药导报, 2023, 20(27): 35-38.

链接本文:

https://www.yiyaodaobao.com.cn/CN/10.20047/j.issn1673-7210.2023.27.07 或 https://www.yiyaodaobao.com.cn/CN/Y2023/V20/I27/35

[1] Xia C，Dong X，Li H，et al. Cancer statistics in China and United States，2022：profiles，trends，and determinants [J]. Chin Med J（Engl），2022，135（5）：584-590.
[2] Siegel RL，Miller KD，Fuchs HE，et al. Cancer statistics，2022 [J]. CA Cancer J Clin，2022，72（1）：7-33.
[3] Rodak O，Peris-Diaz MD，Olbromski M，et al. Current landscape of non-small cell lung cancer：epidemiology，histological classification，targeted therapies，and immunotherapy [J]. Cancers（Basel），2021，13（18）：4705.
[4] Debnath J，Gammoh N，Ryan KM. Autophagy and autophagy- related pathways in cancer [J]. Nat Rev Mol Cell Biol，2023， 24（8）：560-575.
[5] Jain V，Singh MP，Amaravadi RK. Recent advances in targeting autophagy in cancer [J]. Trends Pharmacol Sci，2023，44（5）：290-302.
[6] Yamamoto H，Zhang S，Mizushima N. Autophagy genes in biology and disease [J]. Nat Rev Genet，2023，24（6）：382-400.
[7] Martínez RAS，Pinky PD，Harlan BA，et al. GTP energy dependence of endocytosis and autophagy in the aging brain and Alzheimer’s disease [J]. Geroscience，2023，45（2）：757- 780.
[8] Pradas E，Martinez-Vicente M. The consequences of GBA deficiency in the autophagy-lysosome system in Parkinson’s disease associated with GBA [J]. Cells，2023，12（1）：191.
[9] Zhang Y，Lv W，Li H，et al. Exploring the relationship between autophagy and Gefitinib resistance in NSCLC by silencing PDLIM5 using ultrasound-targeted microbubble destruction technology [J]. Cancer Cell Int，2022，22（1）：293.
[10] Xu W，Zhang M，Li Y，et al. YAP manipulates proliferation via PTEN/AKT/mTOR-mediated autophagy in lung adenocarcinomas [J]. Cancer Cell Int，2021，21（1）：30.
[11] Dong Y，Jin Q，Sun M，et al. CLDN6 inhibits breast cancer metastasis through WIP-dependent actin cytoskeleton- mediated autophagy [J]. J Exp Clin Cancer Res，2023，42（1）：68.
[12] Li N，Zhang X，Chen J，et al. Perturbation of autophagy by a beclin 1-targeting stapled peptide induces mitochondria stress and inhibits proliferation of pancreatic cancer cells [J]. Cancers（Basel），2023，15（3）：953.
[13] Shi J，Guo C，Li Y，et al. The long noncoding RNA TINCR promotes self-renewal of human liver cancer stem cells through autophagy activation [J]. Cell Death Dis，2022，13（11）：961.
[14] Ma F，Ding MG，Lei YY，et al. SKIL facilitates tumorigenesis and immune escape of NSCLC via upregulating TAZ/autophagy axis [J]. Cell Death Dis，2020，11（12）：1028.
[15] Shu F，Xiao H，Li QN，et al. Epigenetic and post-translational modifications in autophagy：biological functions and therapeutic targets [J]. Signal Transduct Target Ther，2023， 8（1）：32.
[16] Hou LS，Zhang YW，Li H，et al. The regulatory role and mechanism of autophagy in energy metabolism-related hepatic fibrosis [J]. Pharmacol Ther，2022，234：108117.
[17] Morozumi Y，Shiozaki K. Conserved and divergent mechanisms that control TORC1 in yeasts and mammals [J]. Genes（Basel），2021，12（1）：88.
[18] Vargas J，Hamasaki M，Kawabata T，et al. The mechanisms and roles of selective autophagy in mammals [J]. Nat Rev Mol Cell Biol，2023，24（3）：167-185.
[19] Vergne I，Roberts E，Elmaoued RA，et al. Control of autophagy initiation by phosphoinositide 3-phosphatase Jumpy [J]. Embo J，2009，28（15）：2244-2258.
[20] Zhang S，Yazaki E，Sakamoto H，et al. Evolutionary diversification of the autophagy-related ubiquitin-like conjugation systems [J]. Autophagy，2022，18（12）：2969-2984.
[21] Zheng X，Yang Z，Gu Q，et al. The protease activity of human ATG4B is regulated by reversible oxidative modification [J]. Autophagy，2020，16（10）：1838-1850.
[22] Li M，Hou Y，Wang J，et al. Kinetics comparisons of mammalian Atg4 homologues indicate selective preferences toward diverse Atg8 substrates [J]. J Biol Chem，2011，286（9）：7327-7338.
[23] Zhen Y，Stenmark H. Autophagosome biogenesis [J]. Cells，2023，12（4）：668.
[24] Mohsen S，Sobash PT，Algwaiz GF，et al. Autophagy agents in clinical trials for cancer therapy：a brief review [J]. Curr Oncol，2022，29（3）：1695-1708.
[25] Soucy TA，Dick LR，Smith PG，et al. The NEDD8 conjugation pathway and its relevance in cancer biology and therapy [J]. Genes Cancer，2010，1（7）：708-716.
[26] Hu R，Li T，Hui K，et al. Apatinib sensitizes chemoresistant NSCLC cells to doxetaxel via regulating autophagy and enhances the therapeutic efficacy in advanced and refractory/recurrent NSCLC [J]. Mol Med Rep，2020，22（5）：3935- 3943.
[27] Cui D，Feng Y，Qian R. Up-regulation of microRNA miR- 101-3p enhances sensitivity to cisplatin via regulation of small interfering RNA （siRNA） anti-human AGT4D and autophagy in non-small-cell lung carcinoma （NSCLC） [J]. Bioengineered，2021，12（1）：8435-8446.
[28] Yuwen D，Ma Y，Wang D，et al. Prognostic role of circulating exosomal miR-425-3p for the response of NSCLC to platinum-based chemotherapy [J]. Cancer Epidemiol Bioma- rkers Prev，2019，28（1）：163-173.
[29] López Plana A，Fernández Nogueira P，Mu?觡oz Guardiola P，et al. The novel proautophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous nonsmall cell lung cancer [J]. Int J Cancer，2020，147（4）：1163-1179.
[30] Sulewska A，Pilz L，Manegold C，et al. A systematic review of progress toward unlocking the power of epigenetics in NSCLC：latest updates and perspectives [J]. Cells，2023，12（6）：905.
[31] Liu S，Li Q，Li G，et al. The mechanism of m6A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by beta-elemene [J]. Cell Death Dis，2020，11（11）：969.
[32] Zhou X，Sun T，Meng Y，et al. BET inhibitors combined with chemotherapy synergistically inhibit the growth of NSCLC cells [J]. Oncol Rep，2021，45（5）：70.
[33] He H，Song X，Yang Z，et al. Upregulation of KCNQ1OT1 promotes resistance to stereotactic body radiotherapy in lung adenocarcinoma by inducing ATG5/ATG12-mediated autophagy via miR-372-3p [J]. Cell Death Dis，2020，11（10）： 883.
[34] Wang J，Hu T，Wang Q，et al. Repression of the AURKA- CXCL5 axis induces autophagic cell death and promotes radiosensitivity in non-small-cell lung cancer [J]. Cancer Lett，2021，509：89-104.
[35] Booth L，Roberts JL，Poklepovic A，et al. [pemetrexed+sildenafil]，via autophagy-dependent HDAC downregulation，enhances the immunotherapy response of NSCLC cells [J]. Cancer Biol Ther，2017，18（9）：705-714.
[36] Limagne E，Ghiringhelli F. Mitophagy：a new actor in the efficacy of chemo-immunotherapy [J]. Autophagy，2022，18（12）：3033-3034.